NASDAQ:EVOK - Evoke Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.11 +0.08 (+2.64 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$3.03
Today's Range$3.01 - $3.11
52-Week Range$1.85 - $3.40
Volume18,400 shs
Average Volume38,006 shs
Market Capitalization$54.20 million
P/E Ratio-3.75
Dividend YieldN/A
Beta2
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.

Receive EVOK News and Ratings via Email

Sign-up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVOK
CUSIPN/A
Phone858-345-1494

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.14 per share

Profitability

Net Income$-12,220,000.00

Miscellaneous

Employees7
Market Cap$54.20 million
Next Earnings Date3/6/2019 (Estimated)
OptionableNot Optionable

Evoke Pharma (NASDAQ:EVOK) Frequently Asked Questions

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

How were Evoke Pharma's earnings last quarter?

Evoke Pharma Inc (NASDAQ:EVOK) posted its earnings results on Tuesday, November, 13th. The specialty pharmaceutical company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.01. View Evoke Pharma's Earnings History.

When is Evoke Pharma's next earnings date?

Evoke Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for Evoke Pharma.

What price target have analysts set for EVOK?

2 brokers have issued 1 year target prices for Evoke Pharma's shares. Their predictions range from $5.00 to $9.00. On average, they anticipate Evoke Pharma's share price to reach $7.00 in the next year. This suggests a possible upside of 125.1% from the stock's current price. View Analyst Price Targets for Evoke Pharma.

What is the consensus analysts' recommendation for Evoke Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evoke Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evoke Pharma.

Has Evoke Pharma been receiving favorable news coverage?

Media coverage about EVOK stock has trended positive recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evoke Pharma earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days.

Who are some of Evoke Pharma's key competitors?

What other stocks do shareholders of Evoke Pharma own?

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the folowing people:
  • Mr. David A. Gonyer, Co-Founder, Chief Exec. Officer, Pres & Director (Age 54)
  • Mr. Matthew J D'Onofrio, Co-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec. (Age 48)
  • Dr. Marilyn R. Carlson, Chief Medical Officer (Age 70)
  • Dr. Wayne Alves, VP of Clinical Operations

Who are Evoke Pharma's major shareholders?

Evoke Pharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.48%) and Wambolt & Associates LLC (0.19%). Company insiders that own Evoke Pharma stock include Kenneth J Widder and Lvp Gp Iii, Llc. View Institutional Ownership Trends for Evoke Pharma.

Which major investors are buying Evoke Pharma stock?

EVOK stock was purchased by a variety of institutional investors in the last quarter, including Wambolt & Associates LLC and BlackRock Inc.. Company insiders that have bought Evoke Pharma stock in the last two years include Kenneth J Widder and Lvp Gp Iii, Llc. View Insider Buying and Selling for Evoke Pharma.

How do I buy shares of Evoke Pharma?

Shares of EVOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $3.11.

How big of a company is Evoke Pharma?

Evoke Pharma has a market capitalization of $54.20 million. The specialty pharmaceutical company earns $-12,220,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Evoke Pharma employs 7 workers across the globe.

What is Evoke Pharma's official website?

The official website for Evoke Pharma is http://www.evokepharma.com.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The specialty pharmaceutical company can be reached via phone at 858-345-1494 or via email at [email protected]


MarketBeat Community Rating for Evoke Pharma (NASDAQ EVOK)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  503
MarketBeat's community ratings are surveys of what our community members think about Evoke Pharma and other stocks. Vote "Outperform" if you believe EVOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Featured Article: Quiet Period

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel